WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
David E. I. PyottDirector2026-06-01921$297.71
$274.19kSell
David E. I. PyottDirector2026-06-0117$302.65
$5.15kSell
David E. I. PyottDirector2026-06-01495$300.72
$148.86kSell
David E. I. PyottDirector2026-06-011,222$299.87
$366.44kSell
David E. I. PyottDirector2026-06-011,175$298.91
$351.22kSell
Amy W. SchulmanDirector2026-05-1311,250$70.20
$789.75kBuy
Melissa McLaughlinChief Human Resources Officer2026-04-06199$333.94
$66.45kSell
Melissa McLaughlinChief Human Resources Officer2026-04-06293$331.89
$97.24kSell
Melissa McLaughlinChief Human Resources Officer2026-04-06829$330.46
$273.95kSell
Melissa McLaughlinChief Human Resources Officer2026-04-06909$329.76
$299.75kSell

1 of 45

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ag Novartis11.09%14,800,620$4.41BInsider
Fmr LLC10.92%14,579,166$4.34BInstitution
Capital World Investors8.09%10,802,348$3.22BInstitution
Sanofi7.90%10,554,134$3.14BInsider
Blackrock Inc7.82%10,444,908$3.11BInstitution
Capital Research Global Investors7.09%9,471,181$2.82BInstitution
Vanguard Portfolio Management LLC4.86%6,491,280$1.93BInstitution
Jpmorgan Chase Co4.74%6,323,752$1.88BInstitution
Vanguard Capital Management LLC4.45%5,946,706$1.77BInstitution
T Rowe Price Investment Management Inc3.89%5,193,324$1.55BInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY82.21%17.79%Net SellingNet Buying
RPRX61.88%17.32%Net SellingNet Selling
RVMD91.08%8.92%Net SellingNet Selling
ONC2.41%31.95%Net SellingNet Selling
ARGX46.56%0.00%
View Top Biotech Stocks

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 96.30% institutional shareholders, 20.84% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.09% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $4.31B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.